Art

J-GLOBAL ID：200902285307960490   Reference number：04A0494103

Orally Active CCR5 Antagonists as Anti-HIV-1 Agents 2: Synthesis and Biological Activities of Anilide Derivatives Containing a Pyridine N-Oxide Moiety

抗HIV1薬としての経口活性CCR5きっ抗薬 2: ピリジンN-オキシド部分を含むアニリド誘導体の合成及び生物活性

Author (9)： SETO M (Takeda Chemical Ind. Ltd., Osaka, JPN) ,  ARAMAKI Y (Takeda Chemical Ind. Ltd., Osaka, JPN) ,  IMOTO H (Takeda Chemical Ind. Ltd., Osaka, JPN) ,  AIKAWA K (Takeda Chemical Ind. Ltd., Osaka, JPN) ,  ODA T (Takeda Chemical Ind. Ltd., Osaka, JPN) ,  KANZAKI N (Takeda Chemical Ind. Ltd., Osaka, JPN) ,  IIZAWA Y (Takeda Chemical Ind. Ltd., Osaka, JPN) ,  BABA M (Kagoshima Univ., Kagoshima, JPN) ,  SHIRAISHI M (Takeda Chemical Ind. Ltd., Osaka, JPN)
Material： Chemical and Pharmaceutical Bulletin  (Chemical & Pharmaceutical Bulletin)
Volume： 52  Issue： 7  Page： 818-829  Publication year： Jul. 01, 2004 
JST Material Number： G0504A  ISSN： 0009-2363  CODEN： CPBTAL  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： *nitrogen heterocyclic compound ,...
Semi thesaurus term： CCケモカイン受容体5

   To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=04A0494103&from=J-GLOBAL&jstjournalNo=G0504A") }}

JST classification (2)： Seven-membered heterocyclic compounds  (CF07110I) ,  Synthesis of drugs  (GV01030F)

Substance index (24)： TAK-779 ,  N-[4-(2-Oxo-2-phospha(V)-1,3,2-dioxaphosphorinane-2-ylmethyl)phenyl]-7-p-tolyl-2,3-dihydro-1-benzoxepin-4-carboxamide ,  N-[4-(1-Oxo-1,1-dihydrophosphorinane-1-ylmethyl)phenyl]-7-p-tolyl-2,3-dihydro-1-benzoxepin-4-carboxamide ,  2-[α-Hydroxy-4-(7-p-tolyl-2,3-dihydro-1-benzoxepin-4-ylcarbonylamino)benzyl]pyridine 1-oxide ,  2-[(αS)-α-Hydroxy-4-[7-[4-(2-butoxyethoxy)phenyl]-1,1-dioxo-2,3-dihydro-1-thia(VI)-1-benzothiepin-4-ylcarbonylamino]benzyl]pyridine 1-oxide ,  2-[(αR)-α-Hydroxy-4-[7-[4-(2-butoxyethoxy)phenyl]-1,1-dioxo-2,3-dihydro-1-thia(VI)-1-benzothiepin-4-ylcarbonylamino]benzyl]pyridine 1-oxide ,  2-[(αS)-α-Hydroxy-4-[7-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-2,3-dihydro-1H-1-benzazepine-4-ylcarbonylamino]benzyl]pyridine 1-oxide ,  2-[(αS)-α-Hydroxy-4-[7-[4-(2-butoxyethoxy)phenyl]-1-(1-methyl-1H-pyrazole-4-ylmethyl)-2,3-dihydro-1H-1-benzazepine-4-ylcarbonylamino]benzyl]pyridine 1-oxide ,  2-[α-Hydroxy-4-[7-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-2,3-dihydro-1H-1-benzazepine-4-ylcarbonylamino]benzyl]-4-methylpyridine 1-oxide ,  2-[α-Hydroxy-2-methyl-4-[7-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-2,3-dihydro-1H-1-benzazepine-4-ylcarbonylamino]benzyl]pyridine 1-oxide ,  2-[α-Hydroxy-2-methoxy-4-[7-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-2,3-dihydro-1H-1-benzazepine-4-ylcarbonylamino]benzyl]pyridine 1-oxide ,  2-[α-Hydroxy-2-chloro-4-[7-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-2,3-dihydro-1H-1-benzazepine-4-ylcarbonylamino]benzyl]pyridine 1-oxide ,  2-[α-Hydroxy-2-(trifluoromethyl)-4-[7-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-2,3-dihydro-1H-1-benzazepine-4-ylcarbonylamino]benzyl]pyridine 1-oxide ,  2-[(αS)-α-Hydroxy-2-(trifluoromethyl)-4-[7-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-2,3-dihydro-1H-1-benzazepine-4-ylcarbonylamino]benzyl]pyridine 1-oxide ,  2-[(αR)-α-Hydroxy-2-(trifluoromethyl)-4-[7-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-2,3-dihydro-1H-1-benzazepine-4-ylcarbonylamino]benzyl]pyridine 1-oxide ,  2-Methyl-4-nitrobenzaldehyde ,  2-Methoxy-4-nitrobenzaldehyde ,  2-Chloro-4-nitrobenzaldehyde ,  α-(2-Pyridyl)-2-methyl-4-aminobenzyl alcohol ,  α-(2-Pyridyl)-2-methoxy-4-aminobenzyl alcohol ,  α-(2-Pyridyl)-2-chloro-4-aminobenzyl alcohol ,  2-(Trifluoromethyl)-4-fluorobenzoic acid ,  α-(2-Pyridyl)-2-(trifluoromethyl)-4-aminobenzyl alcohol ,  7-[4-(2-Butoxyethoxy)phenyl]-2,3-dihydro-1H-1-benzazepine-4-carboxylic acid methyl ester

Reference (19)：

• 1) Carpenter C. C., Fischl M. A., Hammer S. M., Hirsch M. S., Jacobsen D. M., Katzenstein D. A., Montaner J. S., Richman D. D., Saag M. S., Schooley R. T., Thompson M. A., Vella S., Yeni P. G., Volberding P. A., J. Am. Med. Assoc., 280, 78—86 (1998).
• 2) Finzi D., Blankson J., Siliciano J. D., Margolick J. B., Chadwick K., Pierson T., Smith K., Lisziewicz J., Lori F., Flexner C., Quinn T. C., Chaisson R. E., Rosenberg E., Walker B., Gange S., Gallant J., Siliciano R. F., Nat. Med., 5, 512—517 (1999).
• 3) Blair W. S., Lin P. F., Meanwell N. A., Wallace O. B., Drug Discov. Today, 5, 183—194 (2000).
• 4) Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R. E., Hill C. M., Davis C. B., Peiper S. C., Schall T. J., Littman D. R., Landau N. R., Nature (London), 381, 661—666 (1996).
• 5) Dragic T., Litwin V., Allaway G. P., Martin S. R., Huang Y., Nagashima K. A., Cayanan C., Maddon P. J., Koup R. A., Moore J. P., Paxton W. A., Nature (London), 381, 667—673 (1996).

Terms in the title (8)： HIV1 ,  活性 ,  CCR5 ,  きっ抗薬 ,  ピリジンN-オキシド ,  アニリド ,  誘導体 ,  生物活性